SG Americas Securities LLC Invests $829,000 in Organon & Co. (NYSE:OGN)

SG Americas Securities LLC purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 55,670 shares of the company's stock, valued at approximately $829,000.

Several other institutional investors have also recently added to or reduced their stakes in OGN. Millstone Evans Group LLC acquired a new position in Organon & Co. during the 4th quarter worth approximately $29,000. Larson Financial Group LLC grew its holdings in shares of Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after acquiring an additional 1,734 shares in the last quarter. Riverview Trust Co grew its holdings in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after purchasing an additional 1,292 shares during the period. GeoWealth Management LLC bought a new position in Organon & Co. during the fourth quarter valued at $41,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Organon & Co. by 1,795.8% during the fourth quarter. Jones Financial Companies Lllp now owns 4,550 shares of the company's stock worth $68,000 after acquiring an additional 4,310 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Trading Up 0.4%

NYSE OGN opened at $9.89 on Friday. The stock has a market cap of $2.57 billion, a P/E ratio of 3.43, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. The company has a debt-to-equity ratio of 16.49, a quick ratio of 1.15 and a current ratio of 1.67. The stock has a 50 day simple moving average of $9.91 and a two-hundred day simple moving average of $13.27. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.13. Organon & Co. had a return on equity of 227.43% and a net margin of 11.92%. The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same quarter last year, the company earned $1.22 EPS. The firm's revenue for the quarter was down 6.7% on a year-over-year basis. On average, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Monday, May 12th were issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend was Monday, May 12th. Organon & Co.'s payout ratio is 2.78%.

Insider Buying and Selling

In other news, CFO Matthew M. Walsh bought 11,400 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were bought at an average cost of $8.82 per share, for a total transaction of $100,548.00. Following the completion of the transaction, the chief financial officer now owns 144,484 shares of the company's stock, valued at approximately $1,274,348.88. This represents a 8.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daniel Karp bought 3,500 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average price of $8.24 per share, for a total transaction of $28,840.00. Following the completion of the transaction, the vice president now directly owns 46,669 shares of the company's stock, valued at $384,552.56. This represents a 8.11% increase in their position. The disclosure for this purchase can be found here. Insiders bought 102,345 shares of company stock valued at $902,430 over the last 90 days. Company insiders own 1.96% of the company's stock.

Analysts Set New Price Targets

OGN has been the topic of a number of recent analyst reports. Evercore ISI downgraded Organon & Co. from an "outperform" rating to an "inline" rating in a research report on Friday, May 2nd. Piper Sandler reduced their price objective on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Morgan Stanley dropped their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.